Products for Research Use Only
RegisterLogin

Mavacamten (Standard)

CAT: 0804-HY-109037R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109037R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Mavacamten (Standard) is the analytical standard of Mavacamten. This product is intended for research and analytical applications. Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
CAS Number
1642288-47-8
Product Name Alternative
MYK461 (Standard) ; SAR439152 (Standard)
UNSPSC
12352005
Target
Myosin; Reference Standards
Type
Reference Standards
Related Pathways
Cytoskeleton; Others
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/mavacamten-standard.html
Purity
99.74
Smiles
CC(N(C1=O)C(C=C(N[C@H](C2=CC=CC=C2)C)N1)=O)C
Molecular Formula
C15H19N3O2
Molecular Weight
273.33
References & Citations
[1]Kawas RF, et al. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017 Oct 6;292 (40) :16571-16577.|[2]Stern JA, et al. A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy. PLoS One. 2016 Dec 14;11 (12) :e0168407.|[3]Green EM, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016 Feb 5;351 (6273) :617-21.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, sealed storage, away from light and moisture
Scientific Category
Reference Standards

Chemical Information

Mavacamten

Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.

CAS Number1642288-47-8
PubChem CID117761397
IUPAC Name6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione
Molecular FormulaC15H19N3O2
Molecular Weight273.33
XLogP2.1
Topological Polar Surface Area61.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count3
Rotatable Bond Count4
Heavy Atom Count20
Formal Charge0
Complexity411
SMILES
C[C@@H](C1=CC=CC=C1)NC2=CC(=O)N(C(=O)N2)C(C)C
InChI
InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
InChIKey
RLCLASQCAPXVLM-NSHDSACASA-N
Chemical Structure
2D Structure
2D structure of Mavacamten
CAS: 1642288-47-8
CID: 117761397
Formula: C15H19N3O2
MW: 273.33
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight273.33
XLogP32.1
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count3
Rotatable Bond Count4
Exact Mass273.147726857
Monoisotopic Mass273.147726857
Topological Polar Surface Area61.4 Ų
Heavy Atom Count20
Formal Charge0
Complexity411
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Related Products

CatalogName
HY-109037-01Mavacamten
HY-109037S3-01Mavacamten-d5
HY-109037S2Mavacamten-d1
HY-109037SMavacamten-d6
HY-109037S4-01Mavacamten-d7
HY-P2274RArgifin (Standard)
HY-N9362REmodinanthrone (Standard)
HY-N7948RIsomaltotetraose (Standard)
HY-N7640RDeoxylimonin (Standard)
HY-N7617RToralactone (Standard)

Alternative Products

CatalogName
GTR19163735-01Mavacamten
TRC-H299820-10MGHydroxy Mavacamten
TRC-M299820-100MGEnt-Mavacamten
A19326-1Mavacamten 1mg
AR-M03918-01(R) -Mavacamten
CS-O-45810Mavacamten-d6
TRC-M299811-5MGMavacamten-d7
A19326-100Mavacamten 100mg
A19326-25Mavacamten 25mg
CS-O-59155Mavacamten-d5

Popular Products